

Workgroup of European Cancer Patient Advocacy Networks

Activity Report

2022: A YEAR IN REVIEW



WECCAN

Workgroup of European
Cancer Patient Advocacy Networks

Prepared by: European Patient
Advocacy Institute gUG

Published on: January 18, 2023

Index

Table of Contents

2022

A YEAR IN REVIEW



About

A Letter from the Current Chair	03
WECAN Overview	05
Our Network	06
WECAN Over the Years	07
Governance	09
Coordination Team	10
Past and Current Chairs	11
Our Work with the European Patient Advocacy Institute	12

2022 Projects

Ukraine Crisis	
Coordination	14
COVID- 19	16
Education	17
Research	20
Advocacy	21
Funders	25

2023 Plans

2023 Programs and Initiatives	24
-------------------------------------	----

A Letter from the Current Chair

Dear all,

2022 has been an eventful and turbulent year for European cancer patient communities. The year started with periods of regular confinements and 'Zoom contact moments' due to the COVID pandemic and moved towards a slow integration of face-to-face work meetings again.

In September at ESMO in Paris, WECAN members met for the first time face-to-face since 2019. It was so great to see most of the WECAN members both on the podium and in our all-member meeting. Having a taste for going back to face-to-face meetups, we have started planning more moments to meet. In 2023:

- we will have an annual retreat of the WECAN members in Frankfurt to discuss all collaborative projects of WECAN, look at our future opportunities, and raise a glass to the good things in patient advocacy, and
- we will again be hosting the WECAN Academy 4-day face-to-face training event, combining the two leading capacity-building programmes in patient advocacy, WECAN SmartStart and WECAN MasterClass, just as we did before the pandemic.

Learning from the experiences and adapting to the pandemic restrictions, we also continued to invest our efforts in virtual education. In 2022, WECAN launched an eLearning platform with amazing courses to fill the educational gap between face-to-face programmes. We launched a three-module course on GDPR for Patient Organisations to give advocates the knowledge and confidence on how to handle personal and health data. We converted our Evidence-Based Advocacy Training Programme into a full open-access course that provides the Fundamentals of Evidence-Based Advocacy and continued to provide advocates with resources on how to publish their data through our Patients in Publications course. A hybrid approach to project work and education is the new normal.

2022 will also be remembered as the year of the start of a war in Ukraine. At the beginning of the war, it was largely up to our patient communities to help cancer patients and patient groups find a safe haven. The strength of our network was realised through this crisis. Fighting cancer is about saving lives, and in this case, it was mainly about getting patients and their families in Ukraine to a safer place first, and seeing if treatments and care could continue elsewhere.

A Letter from the Current Chair

Through our involvement in preparing the EU Cancer Mission, we will continue to follow the implementation of the Cancer Plan and how it will be translated into concrete results leading to more cures and good care for cancer patients. Not just for the "Big 5" countries in the EU, but for all patients.

Looking to the future, we hope all members will continue their engagement in WECAN programmes through the network of collaboration we built together since 2015 for the cancer patient communities. The focus of our activities remains on advocacy projects that are not disease-specific and that align with our objectives of collaboration and avoidance of duplication of work to save capacity and energy. We hope to also inspire and professionalise European advocacy in general and bring advocacy as a whole to a higher level.

The path to our goals is walked with small, incremental steps. As our shared understanding of the cancer patient communities that we represent grows and evolves, we learn to better represent them, serve them, and build capacity within them to help meet these goals. The broad and diverse project portfolio of WECAN reflects this journey that we are taking together, and the challenges we have faced, and continue to face, along the way.

Although our steps are small, they are bolstered by the knowledge, experience, and skills which we all acquire through our involvement with WECAN. The steps we have taken over the last year have led us closer and closer to a place where patient engagement is truly meaningful and to actions that improve the outcomes for all cancer patients. I am confident that WECAN will make even greater strides towards our goals in the years to come.

I wish you a healthy, joyful and peaceful 2023.

Hans Scheurer

WECAN Chair

Myeloma Patients Europe



WECAN Overview

The Workgroup of European Cancer Patient Advocacy Networks (WECAN) is a network of leaders from 22 cancer patient umbrella organisations active in Europe.

Our mission is to act as a well-coordinated cancer patient community towards all stakeholders by building levels of trust, collaboration, alignment, and mutual support in the pan-European cancer patient community.



Objectives

WECAN serves as a platform for cancer patient organisations to collaborate, learn, and align to strengthen European patient advocacy.



EDUCATION

WECAN creates opportunities to develop patient advocates and organisations with programmes and resources to build their knowledge and expertise



INCREASE ALIGNMENT

WECAN increases the level of alignment, collaboration, and mutual support between pan-European cancer patient umbrella organisations



STRENGTHENING CANCER PATIENT ADVOCACY

Through workstreams in policy, research and capacity building, WECAN aims to strengthen cancer patient advocacy in Europe and improve outcomes for all cancer patients

Our Network




Leaders from pan-European cancer patient umbrella networks form WECAN. In 2022, WECAN's network consisted of 22 organisations representing 27+ disease areas. Each organisation is represented by one member and one alternate.

- Acute Leukemia Advocates Network
- Childhood Cancer International Europe
- CLL Advocates Network
- CML Advocates Network
- Digestive Cancers Europe
- EuropaDonna
- EuropaUomo
- EURORDIS - Rare Diseases Europe
- International Brain Tumour Alliance
- International Kidney Cancer Coalition
- International Neuroendocrine Cancer Alliance
- Lung Cancer Europe
- Lymphoma Coalition
- MDS Alliance
- Melanoma Patients Network Europe
- MPN Advocates Network
- Myeloma Patients Europe
- Pancreatic Cancer Europe Network
- Sarcoma Patients Advocacy Global Network
- Thyroid Cancer Alliance
- World Bladder Cancer Patient Coalition
- Youth Cancer Europe

WECAN Over the Years

Since 2015 WECAN has come together to collaborate and improve the outcomes for cancer patients in Europe.



WECAN Over the Years

2019

The first **WECAN Academy** training programme is hosted in Frankfurt. Over 100 advocates attend the four-day training event that combined **WECAN SmartStart** and **WECAN Masterclass** programmes. Presentations are shared on the **WECAN Knowledge Base**. Myeloma Patients Europe leads the involvement of WECAN in **SISAQOL-IMI**

2020

WECAN expands its educational workstream with the first **WECAN Science** programme held in Brussels hosted by Melanoma Patients Network Europe. 26 participants and 10 faculty attend the two-day training event. A special training programme on **Evidence-Based Advocacy: Evidence Generation and Publications** is initiated as an online webinar series. The **WECAN Academy**, which was planned as an in-person event, shifts to virtual training series due to COVID. WECAN creates a **Virtual Meeting Resource Center** and COVID-19 resource page.

2021

WECAN Governance document is approved by all members. Due to the need for continued education, WECAN expands its educational offerings to an **eLearning platform** and launches the first open-access online course in **Patients in Publications**. WECAN responds to EU Parliament Hearings on Europe's **Beating Cancer Plan**. The first **LivingRoom Conversations** with WECAN is hosted to give WECAN members a place to connect and share experiences.

2022

The **European Atlas on Clinical Trials in Cancer and Hematology**, is launched. The eLearning platform expands with courses on **GDPR** and the **Fundamentals of Evidence-Based Advocacy**. The **EBA Strategy and Design Workshop** connects 8 advocates with EBA experts to launch research projects in 7 therapeutic areas. Through MPE, WECAN collaborates with PFMD on **Global Guidelines for Remunerating the Patient Community**. The network comes together to help Ukrainians in **Ukraine Crisis Coordination**.

Governance


WECAN provides a forum to discuss how and when to collaborate, to share workload and involve one another. WECAN is not a legal entity but an informal network. As an informal network, WECAN retains its independence. The network is governed by a formal governance document which mandates principles around membership and operations.



Members

Being a member of WECAN means opportunities to collaborate, to learn and to grow together. Each member organisation:

- is an umbrella organisation
- is a non-profit
- is led by patients or carers



WECAN Coordination Team

The WECAN Coordination Team consists of the Chair, Past Chair, WECAN coordinators, and any interested WECAN members. The purpose of the WECAN Coordination Team is to provide necessary coordination and administrative functions in order to promote the smooth operation of WECAN in line with its mission, goals and the priorities decided by the WECAN members.



Hans Scheurer
WECAN Chair (2022- Present)

Myeloma Patients Europe



Jan Geißler

CML Advocates Network



Gilly Spurrier

Melanoma Patients
Network Europe



Ananda Plate

Myeloma Patients Europe



Alfonso Aguarón

Lung Cancer Europe



Alison Mendonca

European Patient
Advocacy Institute



Sara Dederichs

European Patient
Advocacy Institute

Past and Current Chairs



Geoff Henning

2018-2019

Digestive Cancers Europe



Ananda Plate

2019- 2020

Myeloma Patients Europe



Gilly Spurrier

2020-2021

Melanoma Patients Network Europe



Jan Geißler

2021-2022

CML Advocates Network



Hans Scheurer

2022- Present

Myeloma Patients Europe

Our Work with the European Patient Advocacy Institute

www.patientadvocacy.eu

WECAN is a network and not a legal entity. As such, WECAN cannot directly receive any funding. Funding for WECAN projects, initiatives, workgroups or programmes is administered by individual organisations associated with WECAN (e.g. MPE, MPNE Support.)

The European Patient Advocacy Institute (EPAI) is a non-profit organisation that has been given the WECAN member's mandate to act as the administrative host for many WECAN projects.

EPAI was set up as a national spin-off from EUPATI. It has evolved as an international platform that hosts large evidence- and education-related advocacy initiatives and programmes for the cancer and hematology patient communities. EPAI leads and guides the development and implementation of methodologies, processes, and projects to strengthen patient advocacy, patient involvement and evidence generation in research, health policy and healthcare services.





Projects

EPAI helps WECAN to achieve its mission to improve the outcomes for all cancer patients. With the mandate written in the WECAN governance, EPAI hosts the following projects for WECAN.

- Courses on Evidence-Based Advocacy
- European Atlas on Clinical Trials in Cancer and Hematology
- Virtual Meetings Resource Center
- WECAN Academy
- WECAN Knowledge Base
- WECAN Secretariat

2022 PROGRAMMES AND INITIATIVES

2022 has been a very busy and successful year for WECAN. From the direction of the WECAN network, guidance of the WECAN Chair, organisation and drive from the Coordination Team, and support from stakeholders, WECAN focused on the following projects and initiatives that were identified as priorities by the cancer patient community.



Ukraine Crisis Coordination

On February 24th, Russia invaded Ukraine. Less than a week later, WECAN came together to support patient organisations to help fleeing Ukrainian cancer patients and their families access the cancer care they needed.

Ukrainian patients with cancer face two battles – surviving a brutal war and surviving a brutal disease. At the beginning of the war, the first healthcare priority was treating conflict-related trauma and injuries; the second was maternal and newborn health then infectious diseases. In the beginning of the war, cancer was relatively low on the priority list of aid agencies.

For the first months of the war in Ukraine, it fell to patient advocacy organisations to fill a gaping hole in the rescue and relocation of Ukrainian refugees with cancer.

As a network of patient organisations, our priority was to establish communication channels, lines of trust, and develop process flows so that patient advocates could get the support and answers they needed to quickly get cancer patients out of Ukraine and into safe-haven countries to continue their cancer treatment.



Ukraine Crisis Coordination

First, a Telegram chat was established to facilitate communication between WECAN and additional European networks to coordinate support activities. The Telegram chat grew to over 40 members with approximately 250 shared links and files.

In daily morning Zoom meetings, WECAN organisations shared experiences, best practices, and trusted resources. The focus was on establishing systematic, solution-based, and scalable processes to provide aid.

Through the quick thinking of MPNE, a Mural was established that organised key information and resources available in bordering countries for cancer patients and their families. The Mural consisted of links, articles, and documents for patient organisations to better assist Ukrainian cancer patients.

This tremendous effort was led by Melanoma Patients Network Europe (MPNE), Lymphoma Coalition, and International Brain Tumor Alliance (IBTA) to whom we are incredibly grateful.

The WECAN network is an example of a united effort. It demonstrates how effectively and efficiently to achieve results and provide a quick response to a humanitarian crisis by strengthening existing networks. The experience gained over the past year has shown us a number of important things: (1) that we must constantly reflect and improve on what we have previously learned; (2) that we should have more of a global focus; (3) that we should not miss gaps and unmet needs; and (4) that, in the future, we should always be ready for a quick response to impending threats and crises that affect the healthcare of cancer patients. Global cooperation is the key to creating a brighter future, as very few problems can be solved by just one organisation. Thus, the WECAN initiative represents an important commitment to current and future generations and can help pave the way for other networks in the face of a similar humanitarian crisis.

[READ MORE](#)

[Cancerworld: Unicorns for Ukraine](#)

[Cancerworld: Crisis in Ukraine](#)

COVID 19

The COVID-19 pandemic caused tremendous disruption to how we live. As a community of cancer patient organisations, patients and caregivers, we have adapted to meet needs. Our workflows have changed to rely on multimedia and digital communication. We have learned how to create apps for patients to share experiences and courses on online learning platforms for continued education. We have disseminated online surveys to understand unmet patient needs and collaborated on important issues like Ukraine and policy actions via Telegram and Zoom. And through the adaptations, our reach has expanded far beyond our fingertips. In some ways, we are more connected now than ever before.

At the onset of the pandemic, we saw a substantial disruption to cancer treatment and care. Initiation and recruitment of clinical trials were delayed, over one million cancer cases were undiagnosed, and 100 million screening tests were not performed.

Just as patient organisations adapted to new ways of working, healthcare centres did too. What was learned through the pandemic may lead to better and novel therapeutic options and improved patient access to clinical trials and healthcare providers.

Now, after almost three years of *dealing with COVID*, the world seems to be shifting back into the pre-pandemic way of living. In 2020, WECAN conducted a GroupMap survey to gather insights on key concerns and challenges faced by cancer patients. The map revealed the effects that would linger beyond the acute crisis. Patient advocates supporting immuno-compromised patients will continue to hold virtual sessions: virtual patient meetings, virtual ad boards, virtual conferences, and virtual training. The financial impact will continue to be a challenge too. For WECAN, as a network of patient organisations, this means finding solutions to meet the needs of the entire patient community and ensuring inclusivity.

[READ MORE](#)

[ESMO](#)

[ECO](#)

[ICBCC](#)

[WECAN Resources](#)



Covid19 has had a huge impact on cancer patients, on delays in diagnosis, follow-up, treatment and management, and we definitely need system catch-up strategies to put this right, but it was also a massive positive disruptor of research and regulatory processes which could be helpful to cancer research collaboration and regulation too. - Gilly Spurrier, MPNE

Education

One of WECAN's key objectives is to increase the capacity and number of well-trained patient advocates in order to further grow a community of activists that can induce change. WECAN educates patient advocates on the three knowledge pillars "Advocacy Tools and Skills", "Healthcare Systems, Policy and Access," and "Research and Data".

WECAN Academy

The WECAN Academy is a training programme for both novice, intermediate and expert patient advocates to enhance their understanding and skills in all areas of advocacy. What started as a four-day training event in 2019 has grown to include a virtual training series and on-demand courses.

In 2020, WECAN planned to host the WECAN Academy's four-day in-person training event for the second time. Due to COVID, the training event was postponed and ultimately cancelled out of concern for our participants and speakers who are mainly cancer patients themselves. To bridge the long gap for the patient advocates since 2019, WECAN transitioned the in-person event into virtual training series from 2021 through 2022. In 2022, the training series completed with 61 participants and 13 virtual trainings.



ACADEMY.WECANADVOCATE.EU
8 COURSES, OVER 100 ENROLLED USERS



Open-access, on-demand courses on Academy.wecanadvocate.eu

In 2022, WECAN continued to expand its educational offerings with the development of a complete web-based e-learning platform. This year we launched courses on:

- Fundamentals of Evidence-Based Advocacy
- GDPR for Patient Organisations
- Understanding the EU Clinical Trial Regulation no. 536/2014

We are currently preparing to develop many more on-demand educational modules on our platform in response to the needs of patient advocates across Europe and beyond.

Available Courses on Academy.wecanadvocate.eu

Fundamentals of Evidence-Based Advocacy

The Fundamentals of EBA teaches patient advocates the importance of generating evidence and how to do it successfully in order to guide healthcare to focus on the true needs of patients. Through a series of webinars, this course walks students through the entire process of an evidence-based generation project.

[TAKE THE COURSE](#)

GDPR for Patient Organisations

Patient organisations need to understand the General Data Protection Regulation (GDPR) and its impact on advocacy work. Co-created with experts in data protection from Fieldfisher, this course teaches patient organisations practical work processes to remain compliant within the GDPR.

[TAKE THE COURSE](#)

Patients in Publications

This course is intended for patient advocates who plan to publish their own research, or who have been invited to be co-authors or peer-reviewers of journal articles. Co-created by patient advocates and medical writing professionals from Envision Pharma Group, this course will help advocates to assess, plan, and publish research in a peer-reviewed journal.

[TAKE THE COURSE](#)

Understanding the EU Clinical Trial Regulation no. 536/2014

The Clinical Trials Regulation (EU) no. 536/2014 came into effect on 31 January 2022. In this course, taught by Laura Pioppo from the European Medicines Agency, advocates learn about the regulation and how clinical trial sponsors, patient advocates, and patients can interact with the public website.

[TAKE THE COURSE](#)

Educational Programmes on Evidence-Based Advocacy (EBA)

Evidence-Based Advocacy (EBA) means advocating in a targeted, scientific, well-educated, and professional manner and measuring the impact of advocacy work. The awareness about and importance of EBA in the patient community has strongly increased over the past years, but, only a small number of patient organisations have the capacity and knowledge of how to generate and use data in advocacy. WECAN's educational programmes on EBA address this educational gap and support patient advocates and organisations in leading their own evidence-generation projects in their indication area.

Since 2020, WECAN has trained advocates on how to run an evidence-generation project and publish the findings. In 2022, to further drive knowledge and skills in EBA and support pan-European cancer patient organisations to develop their own evidence-generation projects, WECAN launched the first **Evidence-Based Advocacy: Strategy and Design Workshop**.

The EBA Strategy and Design Workshop extended the learnings from our **Evidence-Based Advocacy Fundamentals** course and put the theory into practice. From October to November, eight advocates from seven organisations received support from EBA experts from the community. The highly interactive course composed of online course modules, virtual workshops, and group tutoring sessions, enabled advocates to develop and refine an evidence-generation project that was nearly ready to be launched in their therapeutic area.

Learning is ongoing and as advocates implement their projects, more questions will arise. In 2023, WECAN plans to continue to support this first cohort of participants, create an EBA resource centre, and develop additional EBA training modules.

9

Highly interactive virtual sessions divided into three workshops and six group tutoring sessions were delivered over the months of October to November

8

Patient advocates from seven organisations participated in the course

6

Projects in the areas of acute leukemia, childhood cancer, colorectal cancer, bladder cancer and rare diseases were developed



Everyone has provided all the instruments to enable us to design our [evidence generation] project.

- Course participant

Research

WECAN believes in targeted advocacy towards each stakeholder through the use of robust data to communicate patient needs effectively.

SISAQOL- IMI

Setting International Standards of Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials funded by the Innovative Medicines Initiative

SISAQOL- IMI is a public-private collaborative research project that will develop a set of standards for the design, analysis, interpretation, and presentation of Patient Reported Outcome (PRO) data for cancer clinical trials. Myeloma Patients Europe (MPE) are a work package leader in SISAQOL on behalf of WECAN, leading jointly with AbbVie on work package (WP) 8, Patient education, communications and dissemination. This means MPE and WECAN have a pivotal role to play in communicating progress, news, and updates in the consortium and ensuring meaningful dialogue takes place between the patient community and consortium stakeholders so that the results are of true value for cancer patients.



In early 2022, WECAN was involved in reviewing and voting on the first set of recommendations for cancer randomised controlled trials (RCTs) and single-arm studies. Patient advocates sitting on work packages provided the patient perspective during SISAQOL-IMI meetings. To aid patients in understanding the project, a plain language video and a patient-specific webpage on the SISAQOL website were created. Additionally, WECAN and MPE are working on the first two plain-language executive summaries and the plain-language glossary.

Within the educational workstream, MPE and WECAN are developing resources on the use of PROs in cancer clinical trials. The aim is to prepare patient advocates on all the basics of PRO for the final patient educational workshop in 2023.

In 2023, in collaboration with members, MPE and WECAN will continue producing plain language materials and summaries related to the project, increase social media presence, finalise the educational workstream, organise the final educational workshop and review and vote on the next set of recommendations.

EuroACT

In 2022, WECAN, in collaboration with the European hematology patient community, launched Phase 1 of one of the largest research projects conducted by the European cancer patient community: the **European Atlas on Clinical Trials in Cancer and Hematology** (EuroACT). EuroACT aims to understand the clinical trial landscape by analysing where clinical trials are run and which Patient-Reported Outcome Measures (PROMs, e.g, Health-Related Quality of Life) are used in **26 disease areas in cancer and hematology**. Data will be collected through systematic literature reviews and clinical trial registries over the past five years in the European region.

The first time that the entire cancer and hematology patient community comes together to tackle a challenge that affects us all.

Access to clinical trials is a topic that features highly on the agenda of most European patient organisations, particularly those advocating for people living with life-threatening and rare hematological diseases. Patient access to trials is hugely important, not just to access novel therapies, but also because clinical trials improve knowledge, experience, infrastructure and potentially also access to those therapies within that country.




EuroACT

European Atlas on Clinical Trials in Cancer & Hematology

The project is divided into four phases over three years, starting with the data gathering for all 26 disease areas in terms of the clinical trials being held and the use of the PROMs. Through the work of our selected academic partner, [Syreon Research Institute](#), a pilot test in breast cancer to optimise the research protocol has been started. Data collection started in 2022 and will continue into April 2023. It is estimated that 2420 publications regarding PROs will be reviewed.

Results from EuroACT will guide the understanding of inequalities and differences in the availability of clinical trial sites across European countries, and provide evidence on the use of relevant QoL instruments in clinical trials run in the 26 disease areas. It will inform patient advocacy organisations, researchers, and policymakers to make future clinical trials more accessible and more relevant to patients.



Advocacy

WECAN facilitates involvement and alignment between the pan-European cancer patient community and stakeholders.

Multi-Stakeholder Alignment Workgroup on WECAN's Guiding Principles on Reasonable Agreements

The project “Reasonable Agreements between Patient Advocates and Pharmaceutical Companies” was initiated by WECAN in 2016. In 2018 the Guiding Principles were published and, in 2022, a follow-up of the implementation kicked off. In September, delegates from 12 pharmaceutical companies met with WECAN and discussed how the Guiding Principles were implemented and existing challenges. In 2023, WECAN plans to launch educational modules for the patient community on reading legal agreements. WECAN also plans to issue a survey to identify frictions, impact to date, and opportunities.



Global Principles for Remunerating the Patient Community for Interactions with the Pharmaceutical Industry

Using WECAN's Guiding Principles as a reference, Patient Focused Medicines Development (PFMD) and contributors are now driving a comprehensive co-creation effort to establish a trusted process to remunerate the patient community. WECAN, represented by Myeloma Patient Europe (MPE), ensures that the patient's perspective is taken into account.

In 2022, MPE and WECAN hosted virtual workshops to collect feedback from the network on the Global Principles and Global Activity and Expertise Frameworks. The Global Principles harmonised previous work, e.g. the Guiding Principles, so remuneration of the patient community could be handled more consistently and transparently on a global level. These [Global Principles](#) were launched in 2022.

PFMD plans to launch the Global Fair Remuneration Digital Tool in early 2023. The tool will operationalise the Global Principles and apply the Global Activity and Expertise Frameworks to help users define patient engagement activities, identify the right kinds of participants and to agree on remuneration with partners.





WECAN at the European Cancer Summit 2022

Throughout 2022, WECAN members presented WECAN's initiatives and activities in many key international and European meetings and conferences, including:

- ASCO
- ASH
- Cancer Mission
- CDDF
- DIA Europe
- EFPIA
- EHA
- EMA
- EORTC 60th Anniversary
- ESMO
- EUPATI
- Europe's Beating Cancer Plan
- European Cancer Summit
- French EU Presidency
- IMSavar
- Patient Engagement Open Forum
- PFMD

We thank all WECAN members for their important contributions to those meetings.

2023 PROGRAMMES AND INITIATIVES

WECAN Academy Face-to-Face

After three years of virtual meetings, WECAN has taken the decision to organise a face-to-face WECAN Academy on July 1st through July 4th 2023. This will be the second face-to-face WECAN Academy after the big success of the first WECAN Academy meeting in the summer of 2019. The programme will consist of the WECAN Masterclass and WECAN SmartStart to educate both novice and expert patient advocates.

EuroACT Phase 2

Data analysis is the focus of EuroACT, Phase 2. This phase will analyse the data on the availability of clinical trials and the measurement of quality of life for patterns and analytics via two different workstreams. Workstream 1 will be focused on the clinical trial footprint across Europe and Workstream 2 on the PROMs,, including HRQoL, in clinical trials.

Evidence-Based Advocacy

Learning does not stop when a course ends. Participants from Cohort 1 of the EBA: Strategy & Design Workshop will continue to receive support from EBA experts within the community. A second EBA: Strategy & Design Workshop will be offered for the second cohort of participants with the addition of a face-to-face training event. Working with stakeholders such as PFMD and EORTC, WECAN will co-develop training modules on Patient Experience Data.



2022 Funders

We greatly appreciate your support for WECAN's 2022 programmes and initiatives: EuroAct Phase 1, WECAN Academy, and the Evidence-Based Advocacy Strategy and Design Workshop. Funding for these programmes was administered by the European Patient Advocacy Institute.

Abbvie

AstraZeneca

Bayer

Boehringer Ingelheim

Bristol Myers Squibb

Lilly

Incyte

Ipsen

Merck Group

Novartis

Pfizer

Roche

Servier

Takeda

**Thank
You!**

Workgroup of European Cancer Patient Advocacy Networks

WECAN

2022 ACTIVITY REPORT: A YEAR IN REVIEW



Informal network of 22 umbrella
cancer patient advocacy
organisations active in Europe



Info@wecanadvocate.eu
www.wecanadvocate.eu
Academy.wecanadvocate.eu

